

Flow Trial Schedule 2025 – 2026

Accredited Programmes	Trial Issues	APR 25	MAY 25	JUN 25	JUL 25	AUG 25	SEP 25	OCT 25	NOV 25	DEC 25	JAN 26	FEB 26	MAR 26
CD34 Stem Cell Enumeration	4-6	X			X			X			X		
Immune Monitoring	4-6		X			X			X			X	
Leukaemia Immunophenotyping	4-6	X			X					X		X	
Leukaemia Diagnostic Interpretation	4-6		X			X					X		X
Low Level Leucocyte Enumeration	4-6			X			X		X				X
Measurable Residual Disease for ALL by Flow Cytometry	3-4			X				X				X	
Paroxysmal Nocturnal Haemoglobinuria	4-6		x			X			X				x

Non-accredited Programmes	Trial Issues	APR 25	MAY 25	JUN 25	JUL 25	AUG 25	SEP 25	OCT 25	NOV 25	DEC 25	JAN 26	FEB 26	MAR 26
Cerebrospinal Fluid Immunophenotyping Programme	2-3			X			X						
Haematological Malignancy Bone Marrow Aspirate Assessment	2-4	X								X			
Measurable Residual Disease for AML by Flow Cytometry	2-4				X			X					
Measurable Residual Disease for CLL by Flow Cytometry	3-4			x			X				X		
Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry	2-3				X					X			

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping are reliant on patient donations which cannot be guaranteed and may become available at any time. As the shelf life of the samples is limited, we have a restricted window to ship the samples. As such this may affect the trial schedule. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.

Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.

Authorised on: 18-Dec-2024. Authorised by: Samuel Nti. Document Unique Reference: view_only. Due for review on: 18-Dec-2025

Author(s): Samuel Nti